Bleomycin Electrosclerotherapy (BEST) of Slow-Flow Vascular Malformations (SFVMs) in Children

In brief

This study evaluates bleomycin electrosclerotherapy (BEST) as a treatment option for slow-flow vascular malformations in pediatric patients, examining safety profiles, clinical effectiveness, and patient-reported outcomes. The research addresses a gap in pediatric evidence for this interventional technique used to manage venous and lymphatic malformations in children.

• BEST combines bleomycin with electroporation to treat slow-flow vascular malformations in pediatric patients.
• Limited pediatric safety and efficacy data exists for BEST, highlighting need for systematic outcome assessment.
• Study evaluates both clinical effectiveness and patient-reported outcomes to guide treatment decisions.
• BEST offers alternative to traditional sclerotherapy for challenging slow-flow malformations in children.

Written by the GCMD Library team from the article.